- Home
- CSX vs SNY Comparison
CSX vs SNY Comparison
Compare CSX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSX | SNY |
|---|---|---|
| Founded | 1978 | 1994 |
| Country | United States | France |
| Employees | 23000 | 74846 |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.5B | 104.5B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | CSX | SNY |
|---|---|---|
| Price | $50.70 | $42.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 5 |
| Target Price | $43.05 | ★ $58.00 |
| AVG Volume (30 Days) | ★ 13.5M | 3.1M |
| Earning Date | 04-22-2026 | 04-23-2026 |
| Dividend Yield | 1.25% | ★ 3.47% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $10,636,000,000.00 | N/A |
| Revenue This Year | $4.58 | $3.49 |
| Revenue Next Year | $4.89 | $6.10 |
| P/E Ratio | $52.70 | ★ $6.14 |
| Revenue Growth | ★ 17.64 | N/A |
| 52 Week Low | $31.80 | $40.89 |
| 52 Week High | $53.60 | $52.68 |
Technical Indicators
Market Signals| Indicator | CSX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 60.07 | 49.22 |
| Support Level | $44.72 | $42.64 |
| Resistance Level | $53.60 | $43.48 |
| Average True Range (ATR) | 1.14 | 0.71 |
| MACD | -0.12 | -0.12 |
| Stochastic Oscillator | 52.18 | 45.47 |
Price Performance
Historical ComparisonAbout CSX CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue of nearly $14 billion in 2025. On its more than 21,000 miles of track, CSX hauls shipments of coal (16% of consolidated revenue), chemicals (17%), intermodal containers (16%), automotive cargo (7%), and a diverse mix of other bulk and industrial merchandise.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.